Lymphoma is lymphoma, a malignant tumor of the human immune system, which is clinically classified into two categories: Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, among which the most commonly used imported drug used for the treatment of lymphoma is rituximab (Merovia), which is an imported drug for patients with CD20-positive non-Hodgkin’s lymphomas, such as diffuse large B-cell lymphoma, follicular lymphoma, sleeve cell lymphoma, and small cell lymphoma, among others. As long as CD20 is positive, Merovanumab will bind to CD20-positive lymphoma cells, exerting molecular targeting and killing effects, with good therapeutic effects. Meanwhile, rituximab (Merovam) is usually combined with CHOP regimen to achieve better therapeutic effect. Generally the first day of rituximab treatment, the second day of CHOP program chemotherapy. Currently there are many other targeted drugs imported for lymphoma treatment.